Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07112872 · ClinicalTrials.gov registry record · Phase 2

A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes

A Phase 2 study of Type 2 Diabetes Mellitus, sponsored by Hoffmann-La Roche.

Recruiting
Registry status
Phase 2
Development phase
240
Enrollment target
20
Study locations

NCT07112872 is a Phase 2 study of Type 2 Diabetes Mellitus that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 240 participants, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07112872, a Phase 2 study of Type 2 Diabetes Mellitus, is actively recruiting participants, sponsored by Hoffmann-La Roche.

RECRUITING
Registry status
Phase 2
Development phase
240 participants
Enrollment target
20
Study locations

Study Summary

This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

Conditions Studied

Type 2 Diabetes Mellitus

Interventions

  • DRUG Placebo
  • DRUG Semaglutide
  • DRUG RO7795081

Study Locations (20)

California

  • Orange County Research Center - Lake Forest
  • Prospective Research Innovations Inc. - Rancho Cucamonga
  • Encompass Clinical Research - Spring Valley

Florida

  • K2 Medical Research South Orlando, LLC - Clermont
  • Center for Diabetes, Obesity and Metabolism Inc - Pembroke Pines

North Carolina

  • Accellacare of Piedmont Healthcare - Statesville
  • Accellacare of Wilmington, LLC - Wilmington

Tennessee

  • Alliance for Multispecialty Research. LLC - Knoxville
  • Clinical Research Associates - Nashville

Texas

  • Texas Diabetes & Endocrinology, P.A. - Austin
  • Apex Mobile Clinical Research - Bellaire

Arizona

  • Arizona Liver Health - Tucson - Tucson

Connecticut

  • Chase Medical Research - Waterbury

District of Columbia

  • Emerson Clinical Research Institute - Washington D.C.

Trial Details

FieldValue
Enrollment Target 240 participants
Start Date 2025-08-19
Est. Completion 2027-02-08
Phase Phase 2

Sponsor

Hoffmann-La Roche

909 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07112872

The ClinicalTrials.gov registry entry for NCT07112872 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,746-participant average among 122 other Type 2 Diabetes Mellitus trials with a reported enrollment target (91% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT07112872 reports 20 study locations spanning 14 distinct geographic areas - top geographies include California, Florida, North Carolina.

Frequently Asked Questions

What is clinical trial NCT07112872 about?

NCT07112872 is a clinical study titled "A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes". This multicenter, randomized, double-blind, placebo- and open-label active comparator-controlled, parallel-group, dose-range-finding, Phase II study aims to evaluate the efficacy, tolerability, and safety of RO7795081 for glycemic control in adult participants with Type 2 diabetes mellitus (T2D).

What is the current status of trial NCT07112872?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2025-08-19. Estimated completion is 2027-02-08.

What conditions does trial NCT07112872 study?

This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.

What interventions are being tested in trial NCT07112872?

The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG), RO7795081 (DRUG).

Who is sponsoring clinical trial NCT07112872?

This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07112872 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Type 2 Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Type 2 Diabetes Mellitus

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.